Indivior PLC has announced its decision to cancel its secondary listing on the London Stock Exchange while maintaining its primary listing on the Nasdaq. This move comes after a thorough review by the company’s board, considering factors such as trading volumes, shareholder locations, and the costs associated with the London listing.
In a circular published previously, the board had indicated its intention to retain the secondary listing in London as long as it benefited the company and its shareholders. However, following the completion of its transition to a U.S. primary listing, the board has now determined that delisting from the London Stock Exchange would be advantageous for several reasons.
The decision to delist from the London Stock Exchange aligns with Indivior’s strategic focus on its U.S. operations, particularly its SUBLOCADE product. With the majority of its revenue coming from the U.S., the board believes that a single primary listing on Nasdaq better represents the company’s business profile.
Moreover, the move is expected to simplify the company’s listing structure, reduce costs, and streamline administrative processes. Liquidity on Nasdaq has significantly surpassed that on the LSE, with the majority of shareholders now based in the U.S.
David Wheadon, Chair of Indivior, expressed satisfaction with this decision, highlighting the expected benefits in terms of cost savings and operational efficiency. The company has initiated the process of delisting from the London Stock Exchange, with the effective date set for July 25, 2025.
Following the delisting, trading of Indivior’s shares will no longer be possible on the LSE, but the company will continue to maintain its listing on Nasdaq. Shareholders holding U.K. issued Indivior Depositary Interests (DIs) and participants in the Corporate Sponsored Nominee facility are advised to review the details provided by the company for the post-delisting arrangements.
As part of this delisting process, Indivior will ensure compliance with the Takeover Code, which applies to companies with equity securities traded on U.K. regulated markets. The company will continue to adhere to the Code’s provisions for a period of two years post-delisting.
Indivior has also issued a cautionary note regarding forward-looking statements, emphasizing the inherent uncertainties and risks associated with such statements. The company remains committed to its vision of developing treatments for opioid use disorder and transforming it into a recognized and treated chronic disease.
As Indivior progresses with its delisting from the London Stock Exchange, shareholders are encouraged to stay informed about the process and take necessary actions to ensure a smooth transition in their holdings.
📰 Related Articles
- London Stock Exchange Group Plc: Mixed Prospects for Investors
- How London Stock Exchange Group Surged in Q1 2025 with FX Revenue Growth
- How Coca-Cola Europacific Partners PLC Utilized London Stock Exchange for Share Buyback Program
- Why Did ITM Power Stock Dip on London Stock Exchange?
- Wellnex Life Secures $14.3M Funding for London Stock Exchange